Join the 'Hemosiderosis' group to help and get support from people like you.
Posted 14 Oct 2011 by Drugs.com
October 14, 2011 – The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy. Patients with thalassemia have excess iron in the body from the frequent blood transfusions (transfusional iron overload), a condition that is serious and can be fatal. These patients also have a risk of developing liver disease, diabetes, arthritis, heart failure or an abnormal heart rhythm. The standard of care to treat transfusional iron overload is chelation therapy – chemical agents that are used to remove heavy metals from the body. Ferriprox is intended for use when chelation therapy is inadequate. “Ferriprox represents the first new FDA-approved treatment for this disorder since 2005,” s ... Read more
Related support groups: Hemosiderosis